FDA OKs First Medical Device To Treat Attention-Deficit/Hyperactivity Disorder In Children

The U.S. Food and Drug Administration (FDA) recently announced it is giving the OK for the first medical device to treat attention-deficit/hyperactivity disorder (ADHD) in children. The device is created by Los Angeles, California-based life sciences organization NeuroSigma. NeuroSigma, Inc. is currently working on trigeminal nerve stimulation for a variety of disorders, including ADHD, epilepsy, depression, post-traumatic stress disorder, Lennox-Gastaut syndrome, and traumatic brain injury.

NeuroSigma’s Monarch external Trigeminal Nerve Stimulation (eTNS) System, is a device that is intended for children ages 7 to 12 who are not currently receiving prescription medication for . . .